Against TREATing all patients alike: Lessons from an FDA advisory committee meeting

Journal of the American Society of Nephrology

Volumn 22, Issue 1, 2011, Pages 1-2

  Winkelmayer, Wolfgang C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO;

ADVISORY COMMITTEE; ANEMIA; BLOOD PRESSURE MEASUREMENT; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION RISK; MEDICAL SOCIETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTE COUNT;

EID: 78651386016     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2010111133     Document Type: Editorial

References (10)

1. Singh AK: Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia - Pro. J Am Soc Nephrol 20: 1436-1441, 2009
2. Himmelfarb J, Szczech LA: Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia - Con. J Am Soc Nephrol 20: 1441-1443, 2009
3. Winkelmayer WC: Testimony on behalf of the American Society of Nephrology before the Cardiovascular and Renal Drug Advisory Committee of the U.S. Food and Drug Administration, October 18, 2010. Available at: http://asn-online.org/ policy-and-public-affairs/docs/ Testimony%20on%20behalf%20of%20the%20American %20Society %20of%20Nephrology%20before %20the %20Cardiovascular%20and%20Renal%20Drug%20Advisory%20Committee%20of%20the%20U.S. %20Food%20and%20Drug%20Administration.pdf. Accessed November 8, 2010
4. U.S. Food and Drug Administration: Briefing Information for the October 18, 2010 Meeting of the Cardiovascular and Renal Drugs Advisory Committee. Available at: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ucm229325.htm. Accessed October 25, 2010
5. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006
6. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006
7. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019-2032, 2009
8. Singh AK: Does TREAT give the boot to ESAs in the treatment of CKD anemia? J Am Soc Nephrol 21: 2-6, 2010
9. Unger EF, Thompson AM, Blank MJ, Temple R: Erythropoiesis-stimulating agents: Time for a reevaluation. N Engl J Med 362: 189-192, 2010
10. Hadland BK, Longmore GD: Erythroid-stimulating agents in cancer therapy: Potential dangers and biologic mechanisms. J Clin Oncol 27: 4217-4226, 2009